Skip to main content

Table 3 Inclusion criteria for primary and secondary data collection

From: Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol

Primary data study participant group

Primary data inclusion criteria

Local site physician champion

Submit an application for BHAP program enrollment

Multidisciplinary local site pediatric oncology staff

Attend both 90-min synchronous training sessions or watch session recording online

Local site implementation team

Will include a minimum of 2 physicians, 2 nurses, and 1 pharmacist at each LMIC site, who attended both training sessions and participated in frontline management of patients receiving blinatumomab in the inpatient setting

Key stakeholders

Representatives from the pharmaceutical company actively involved in the drug donation program

Representatives from St. Jude actively involved in the BHAP program

LMIC site implementation team

Secondary data study participant group

Secondary data inclusion criteria

Patients

Satisfy BHAP program enrollment criteria to receive blinatumomab, parental consent to receive blinatumomab (obtained by a local physician), and initiate blinatumomab infusion

  1. LMIC Low- and middle-income countries, BHAP Blincyto® Humanitarian Access Program